Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ACNS1022||COG||A Phase II Randomized Trial of Lenalidomide (NSC # 703813; IND # 70116) in Pediatric Patients with Recurrent; Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas: A Groupwide Phase II Study||Pediatric CIRB||Available to Open|
|AALL0932||COG||Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)||Pediatric CIRB||Available to Open|
|PBTC-055||PBTC||Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults||Pediatric CIRB||Available to Open|
|ANBL00B1||COG||Neuroblastoma Biology Studies||Pediatric CIRB||Available to Open|
|AALL03N1||COG||Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia||Pediatric CIRB||Available to Open|
|ADVL1412||COG||A Phase 1/2 Study of Nivolumab (IND# 124729) in Children; Adolescents; and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab||Pediatric CIRB||Available to Open|
|AREN0534||COG||Treatment for Patients with Bilateral; Multicentric; or Bilaterally-Predisposed Unilateral Wilms Tumor: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AAML07P1||COG||A Phase II Pilot Study of Bortezomib (PS-341; Velcade; IND# 58;443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent; Refractory or Secondary Acute Myeloid Leukemia||Pediatric CIRB||Completed|
|PEPN1812||PEP-CTN||A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND #145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|
|ADVL1712||COG||A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome||Pediatric CIRB||Available to Open|